ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions
Launched by EISAI GMBH · Mar 16, 2017
Trial Information
Current as of June 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Partial onset seizures with or without secondary generalisation in conjunction with a diagnosed epilepsy of symptomatic or unknown course.
- • 2. The decision to prescribe Eslicarbazepine acetate (ESL) was taken independent of and prior to enrollment into this study.
- • 3. Treatment with ESL is in agreement with the valid summary of product characteristics (SmPC) version, particularly with the licensed indication.
- • 4. Age 18 years and older.
- • 5. Participant's written consent.
- Exclusion Criteria:
- • 1. Known psychogenic non-epileptic attacks.
- • 2. Participation in an interventional study.
- • 3. Previous enrollment in the current study.
About Eisai Gmbh
Eisai GmbH is a leading global pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs. With a strong focus on neurology and oncology, Eisai is committed to improving patient outcomes through the discovery and delivery of effective medicines. The company leverages advanced scientific expertise and collaborative partnerships to drive clinical trials and enhance therapeutic options, all while adhering to the highest standards of ethical practice and regulatory compliance. Eisai GmbH is part of the Eisai Co., Ltd. group, headquartered in Japan, and continues to expand its impact in the healthcare sector across Europe and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials